New Bispecific Antibody AZD0486 for Relapsed/Refractory Lymphoma

We had the privilege of featuring Dr. Ryan Jacobs, lymphoma specialist at Levine Cancer Institute. He shared insights from the early trials with AZD0486, a new bispecific antibody that has the potential to help lymphoma patients with relapsed or refractory disease (NCT04594642). 

Follicular lymphoma can have periods of relapse and remission. Unfortunately, in some cases, the treatments are less effective with each relapse. It is even more challenging for relapsed/refractory patients who fail CAR T-cell therapy or CD20 bispecific antibodies because of the lack of options. 

What makes AZD0486 a better option for relapsed/refractory lymphoma patients? 

The downside of CD19 CAR T-cell therapies is that not everybody has access to them, and some patients can’t wait. On the other hand, CD20 bispecific antibodies are limited by CD20 antigen loss. 

AZD0486 is a new bispecific CD19xCD3 antibody that induces T-cell–mediated cancer cell destruction with a reduced cytokine release, indicating that it could be an efficacious and safer option for relapsed and refractory lymphoma patients. 

What Does this Trial with AZD0486 Consist of? 

AZD0486 was administered intravenously in doses ranging from 0.03 to 2.4 mg and given every two weeks over 28-day cycles for up to 2 years.

So far, a total of 17 patients with a median age of 68 years have received AZD0486. All of them had prior CD20 antibody therapy, with many having received additional treatments like alkylating agents (cisplatin, or melphalan) and CAR T-cell therapy.  

What Are the Early Trial Results? 

Since it’s in phase 1 and still recruiting, researchers need more time to confirm the results. However, so far, the study has shown high complete remission rates induced by this new therapy during early-phase dose escalation. With the information available so far, it appears that the responses are durable and that the side effects are manageable. 
Regarding side effects, so far, no severe cytokine release syndrome (CRS) has been observed. In 24% of patients, mild to moderate neurological events were reported, with only one severe case.

Who Can Participate? 

This ongoing recruiting trial is designed for relapsed and refractory lymphoma patients who have undergone multiple treatments unsuccessfully. 
Patients with B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, high-grade B-cell lymphoma, and follicular lymphoma can be eligible to receive AZD0486 therapy. You can check if this trial is recruiting near you with the Healthtree Clinical Trial Finder.

Stay Updated on Treatment Advances, News, and more with HealthTree, The Platform That Powers Life-Saving Research!

You can stay informed and continue to explore other educational resources. 
 

KEEP EXPLORING

Sources: 

• A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
• HIGH COMPLETE RESPONSE RATE WITH TNB-486, A NOVEL CD19XCD3 T-CELL ENGAGER, IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM AN ONGOING PHASE 1 STUDY
• AZD0486, A NOVEL CD19XCD3 T-CELL ENGAGER, SHOWS DURABLERESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULARLYMPHOMA: UPDATE ON EFFICACY AND SAFETY